Achieve Life Sciences, Inc.
ACHV
$0.03
Change (1 day)
$5.98
Year High
$3.03
Year Low
Categories
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Achieve Life Sciences, Inc. (ACHV) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 111 K | 1.19 M | 20.82 M | 19.37 M | 16.98 M |
| 2022 | 105 K | -8,573,000 | 21.67 M | 29.97 M | 24.84 M |
| 2021 | 153 K | -42,949,000 | 19.47 M | 47.52 M | 44.59 M |
| 2020 | -35,684,000 | 3.01 M | 40.3 M | 36.98 M | |
| 2019 | 8 K | -16,302,000 | 3.03 M | 21.08 M | 17.38 M |